OncLive SOSS

Refining Treatment Approaches for Chronic Lymphocytic Leukemia - Episode 18

CLL: Final Thoughts

September 7, 2021

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, John Allan, MD, Weill Cornell Medicine, Ehab Atallah, MD, Medical College of Wisconsin, Steven Coutre, MD, Stanford University Medical Center, Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, Jennifer Woyach, MD, Ohio State University

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: CLL: Evolution of Treatment

EP. 2: Molecular Testing for Newly Diagnosed CLL

EP. 3: Prognostic Factors in Chronic Lymphocytic Leukemia

EP. 4: CLL: Prognostic Markers

EP. 5: Long-Term Experience With Ibrutinib in CLL

EP. 6: BTK Inhibitors as Frontline Treatment for CLL

EP. 7: Safety and Efficacy of BTK Inhibitors in CLL

EP. 8: Mitigating Toxicities Associated With BTK Inhibitors

EP. 9: ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL

EP. 10: BCL2 Inhibitors in Previously Untreated CLL

EP. 11: CLL Therapies: Novel Combinations

EP. 12: CLL: GLOW Trial Overview

EP. 13: CLL: BTK Inhibitors in the R/R Setting

EP. 14: High-Risk Patients With R/R CLL

EP. 15: CLL: Venetoclax in the R/R Setting

EP. 16: PI3K inhibitors for R/R CLL

EP. 17: Emerging Agents for R/R CLL

EP. 18: CLL: Final Thoughts

x